Provided by Tiger Trade Technology Pte. Ltd.

Tiziana Life Sciences PLC

1.15
+0.01000.88%
Post-market: 1.14-0.0100-0.87%16:47 EDT
Volume:958.92K
Turnover:1.14M
Market Cap:146.05M
PE:-7.38
High:1.25
Open:1.14
Low:1.14
Close:1.14
52wk High:2.35
52wk Low:0.8663
Shares:127.00M
Float Shares:64.88M
Volume Ratio:0.60
T/O Rate:1.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1558
EPS(LYR):-0.1558
ROE:-924.32%
ROA:-115.96%
PB:2808.65
PE(LYR):-7.38

Loading ...

Tiziana Life Sciences Launches Phase 2a Banyan Trial of Intranasal Foralumab in ALS

Reuters
·
Yesterday

Tiziana Life Sciences Announces Poster Presentation on Phase 2a Banyan Clinical Trial of Intranasal Foralumab at ALS Nexus 2026

THOMSON REUTERS
·
Yesterday

Tiziana Life Sciences CEO Elrifi Buys USD 321,423 in Shares

Reuters
·
Aug 06

Press Release: Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

Dow Jones
·
Aug 06

Tiziana CEO Ivor Elrifi Acquires 667,000 Common Shares for $667,000

Reuters
·
Aug 06

Tiziana Life Sciences CEO Ivor Elrifi Lifts Stake to 4,472,261 Shares After Buying 667,000 at $1 Apiece

Reuters
·
Aug 04

Press Release: Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

Dow Jones
·
Aug 04

Tiziana Reports up to 34% Drop in Brain Inflammation in Third MSA Patient on Intranasal Foralumab in Phase 2 Trial

Reuters
·
Jul 31

Tiziana Life Sciences - Third MSA Patient Shows up to 34% Reduction in SUV and 26% in Suvr in Brain Regions

THOMSON REUTERS
·
Jul 31

Tiziana Life Sciences - to Continue Evaluating Intranasal Foralumab in Additional MSA Patients

THOMSON REUTERS
·
Jul 31

Tiziana Life Sciences CEO Ivor Elrifi Files Initial Beneficial Ownership Statement

Reuters
·
Jul 24

Tiziana Life Sciences Chairman Cerrone Raises Stake to 34.93% After Buying 42,357 Shares at $0.99

Reuters
·
Jul 22

Tiziana Life Sciences Completes First Dosing in Phase 2 Inform-ms Trial of Intranasal Foralumab in Secondary Progressive MS

Reuters
·
Jun 25

Tiziana Announces Last Patient Successfully Dosed in Its Phase 2 Inform-ms Trial

THOMSON REUTERS
·
Jun 25

Tiziana Life Sciences - Topline Data from Inform-ms Trial Expected Late Q3 or Early Q4 2026

THOMSON REUTERS
·
Jun 25

Tiziana Life Sciences Executive Chairman Gabriele Cerrone Increases Holdings

MT Newswires Live
·
Jun 15

Tiziana Life Sciences’ COO and CFO Keeren Shah files initial beneficial ownership statement

Reuters
·
May 23

Tiziana Life Sciences Completes Patient Enrollment for Phase 2a Multiple Sclerosis Trial

MT Newswires Live
·
May 21

Tiziana fully enrolls Phase 2 placebo-controlled MS trial

TIPRANKS
·
May 21

Tiziana completes enrollment in Phase 2a intranasal foralumab trial in secondary progressive MS

Reuters
·
May 21